Protective effects of rutin on liver injury in type 2 diabetic db/db mice

Biomedicine and Pharmacotherapy

Volumn 107, Issue , 2018, Pages 721-728

  Liang, Weishi ^a   Zhang, Dandan ^a   Kang, Jiali ^a   Meng, Xubing ^a   Yang, Jingbo ^a   Yang, Lei ^a   Xue, Ning ^a   Gao, Qingyao ^a   Han, Shuying ^a   Gou, Xiangbo ^a  

^a NORTH CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Advanced glycation end products; HepG2 cells; Insulin signal pathway; Liver injury; Rutin; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RUTOSIDE; INSULIN RECEPTOR SUBSTRATE; PROTECTIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL COUNTING; CELL DEGENERATION; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN FIBER; CONTROLLED STUDY; DB/DB MOUSE; DRUG MECHANISM; DRUG MEGADOSE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; HEP-G2 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LOW DRUG DOSE; MALE; MORNING DOSAGE; MOUSE; MRNA EXPRESSION LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BLOOD; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMAN; INJURIES; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; GLYCATION END PRODUCTS, ADVANCED; GLYCOGEN SYNTHASE KINASE 3 BETA; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; LIVER; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RUTIN; SIGNAL TRANSDUCTION;

EID: 85051658950     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.08.046     Document Type: Article

References (43)

1. Piniés, J.A., González-Carril, F., Arteagoitia, J.M., Irigoien, I., Altzibar, J.M., Rodriguez-Murua, J.L., et al. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). Diabetologia 57:11 (2014), 2324–2333.
2. Wu, D., Xuan, Y., Ruan, Y., Feng, X., Zhu, Y., Jia, C., et al. Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre. Diab. Vasc. Dis. Res. 13:1 (2016), 21–30.
3. Hsiang, J.C., Gane, E.J., Bai, W.W., Gerred, S.J., Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J. Gastroenterol. Hepatol. 30:3 (2015), 591–599.
4. Shima, T., Uto, H., Ueki, K., Takamura, T., Kohgo, Y., Kawata, S., et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J. Gastroenterol. 48:4 (2013), 515–525.
5. Su, Q., Sun, F., Li, J., Zhang, H., Wang, M., Zhou, H., et al. The correlation analysis of primary liver cancer with type 2 diabetes. Indian J. Cancer 52:7 (2015), 148–152.
6. Davis, T.M., Peters, K.E., Bruce, D.G., Davis, W.A., Prevalence, incidence, and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the Fremantle diabetes study. J. Clin. Endocrinol. Metab. 97:5 (2012), 1581–1588.
7. Czech, M.P., Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23:7 (2017), 804–814.
8. Sheelagh, F., Daniella, Z., Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin. Ther. Targets 10:3 (2006), 429–444.
9. Yamagishi, S., Nakamura, N., Suematsu, M., Kaseda, K., Matsui, T., Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol. Med. 21:Suppl 1 (2015), S32–S40.
10. Hsu, C.Y., Shih, H.Y., Chia, Y.C., Lee, C.H., Ashida, H., Lai, Y.K., et al. Rutin potentiates insulin receptor kinase to enhance insulin-dependent glucose transporter 4 translocation. Mol. Nutr. Food Res. 58:6 (2014), 1168–1176.
11. Yoo, H., Ku, S.K., Baek, Y.D., Bae, J.S., Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo. Inflamm. Res. 63:3 (2014), 197–206.
12. Soares, J.M.D., Leal, A.E.B.P., Silva, J.C., Almeida, J.R.G.S., Oliveira, H.P.D., Influence of flavonoids on mechanism of modulation of insulin secretion. Pharmacogn. Mag. 13:52 (2017), 639–646.
13. Júnior, I.I.D.S., Barbosa, H.D.M., Carvalho, D.C.R., Barros, R.D.A., Albuquerque, F.P., Silva, D.H.A.D., et al. Brazilian Morus nigra attenuated hyperglycemia, dyslipidemia, and prooxidant status in alloxan-induced diabetic rats. Transfus. Apher. Sci., 2017(1), 2017, 5275813.
14. Pan, P.H., Lin, S.Y., Wang, Y.Y., Chen, W.Y., Chuang, Y.H., Wu, C.C., et al. Protective effects of rutin on liver injury induced by biliary obstruction in rats. Free Radic. Biol. Med. 73:2 (2014), 106–116.
15. Zargar, S., Wani, T.A., Alamro, A.A., Ganaie, M.A., Amelioration of thioacetamide-induced liver toxicity in Wistar rats by rutin. Int. J. Immunopathol. Pharmacol. 30:3 (2017), 207–214.
16. Liu, Q., Pan, R., Ding, L., Zhang, F., Hu, L., Ding, B., et al. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries. Int. Immunopharmacol. 49 (2017), 132–141.
17. Jadeja, R.N., Devkar, R.V., Nammi, S., Oxidative stress in liver diseases: pathogenesis, prevention, and therapeutics. Oxid. Med. Cell. Longev. 2017 (2017), 1–2.
18. Cichoż-Lach, H., Michalak, A., Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol. 20:25 (2014), 8082–8091.
19. Yilmaz, Y., Senates, E., Yesil, A., Ergelen, R., Colak, Y., Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J. Diabetes Complications 28:3 (2014), 328–331.
20. Gou, X.B., Han, S.Y., Xu, J.M., Yu, H., Chu, J.X., Wang, Z.L., et al. Effect of total flavones of buckwheat flowers and leaves on protein tyrosine phosphatase 1B expression in type 2 diabetic rats. Lat. Am. J. Pharm. 30:7 (2011), 1377–1382.
21. Ahmed, O.M., Moneim, A.A., Yazid, I.A., Mahmoud, A.M., Antihyperglycemic, antihyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens infusion and rutin in nicotinamide-streptozotocin-induced diabetic rats. Diabetol. Croat. 39:1 (2010), 15–35.
22. Fernandes, A.A., Novelli, E.L., Okoshi, K., Okoshi, M.P., Muzio, B.P., Guimarães, J.F., et al. Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomed. Pharmacother. 64:3 (2010), 214–219.
23. Ghorbani, A., Mechanisms of antidiabetic effects of flavonoid rutin. Biomed. Pharmacother. 96 (2017), 305–312.
24. Kamalakkannan, N., Stanely, M.P.P., Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues. Mol. Cell. Biochem. 293:1 (2006), 211–219.
25. Kandarakis, S.A., Piperi, C., Topouzis, F., Papavassiliou, A.G., Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog. Retin. Eye Res. 42:9 (2014), 85–102.
26. Gautieri, A., Passini, F.S., Silván, U., Guizar-Sicairos, M., Carimati, G., Volpi, P., et al. Advanced glycation end-products: mechanics of aged collagen from molecule to tissue. Matrix Biol. 59 (2016), 95–108.
27. Aydın, A.F., Bingül, İ., Küçükgergin, C., Doğan-Ekici, I., Doğru Abbasoğlu, S., Uysal, M., Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats. Int. J. Exp. Pathol. 98:5 (2017), 278–288.
28. Huang, R., Shi, Z., Chen, L., Zhang, Y., Li, J., An, Y., Rutin alleviates diabetic cardiomyopathy and improves cardiac function in diabetic ApoEknockout mice. Eur. J. Pharmacol. 814 (2017), 151–160.
29. Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R.M., et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 287:5 (2004), G1035–G1043.
30. Hazlehurst, J.M., Conor, W., Thomas, M., Cobbold, J.F., Tomlinson, J.W., Non-alcoholic fatty liver disease and diabetes. Metabolism 65:8 (2016), 1096–1108.
31. Masarone, M., Rosato, V., Aglitti, A., Bucci, T., Caruso, R., Salvatore, T., et al. Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage. Dig. Liver Dis., 48(Suppl 3), 2016, e237.
32. Perazzo, H., Dufour, J.F., The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 37:5 (2017), 634–647.
33. Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6:4 (2004), 351–357.
34. Ide, N., Arisawa, K., Ogura, K., Kagawa, Y., Maeda, T., Age-dependent onset of insulin resistance in insulin-resistant mice. Biol. Pharm. Bull. 38:12 (2015), 1925–1934.
35. Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, M.S., Goldstein, J.L., Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6:1 (2000), 77–86.
36. Hou, G.J., Li, C.N., Huan, Y., Liu, S.N., Liu, Q., Liu, M.Z., et al. The PI3K/Akt1-FoxO1 translocation pathway mediates EXf effects on NIT-1 cell survival. Exp. Clin. Endocrinol. Diabetes 125:10 (2017), 669–676.
37. Liu, Q.P., Li, X., Li, C.Y., Zheng, Y.F., Wang, F., Li, H.Y., et al. 1-deoxynojirimycin alleviates liver injury and improves hepatic glucose metabolism in db/db mice. Molecules, 21(3), 2016, 279.
38. Zhang, Y., Takemori, H., Wang, C., Fu, J., Xu, M., Xiong, L., et al. Role of salt inducible kinase 1 in high glucose-induced lipid accumulation in HepG2 cells and metformin intervention. Life Sci. 173 (2017), 107–115.
39. Dkhar, B., Khongsti, K., Thabah, D., Syiem, D., Satyamoorthy, K., Das, B., Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice. J. Cell. Biochem. 119:2 (2018), 1953–1970.
40. Jiang, B., Le, L., Zhai, W., Wan, W., Hu, K., Yong, P., et al. Protective effects of marein on high glucose-induced glucose metabolic disorder in HepG2 cells. Phytomedicine 23:9 (2016), 891–900.
41. Song, J.J., Wang, Q., Du, M., Li, T.G., Chen, B., Mao, X.Y., Casein glycomacropeptide-derived peptide IPPKKNQDKTE ameliorates high glucose-induced insulin resistance in HepG2 cells via activation of AMPK signaling. Mol. Nutr. Food Res., 61(2), 2017.
42. Nie, J., Chang, Y., Li, Y., Zhou, Y., Qin, J., Sun, Z., et al. Caffeic acid phenethyl ester (propolis extract) ameliorates insulin resistance by inhibiting JNK and NF-κB inflammatory pathways in diabetic mice and HepG2 cell models. J. Agric. Food Chem. 65:41 (2017), 9041–9053.
43. Liu, Z.Q., Liu, T., Chen, C., Li, M.Y., Wang, Z.Y., Chen, R.S., et al. Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice. Toxicol. Appl. Pharmacol. 285:1 (2015), 61–70.